Cho AJin, Jeong Seon A, Park Hayne Cho, Kim Do Hyoung, Yoo Kyung Don, Yoon Hye Eun, Kim Yang Gyun, Lee Young-Ki
Department of Internal Medicine, Kangnam Sacred Heart Hospital, Seoul, Republic of Korea.
Hallym Kidney Research Institute, Hallym University College of Medicine, Seoul, Republic of Korea.
Kidney Res Clin Pract. 2025 May;44(3):500-509. doi: 10.23876/j.krcp.23.287. Epub 2024 May 29.
Patients with end-stage kidney disease (ESKD) are more susceptible to viral epidemics and are known to have higher incidence and death rates of coronavirus disease 2019 (COVID-19) compared to the general population. We determined COVID-19 incidence and mortality among chronic hemodialysis (HD), peritoneal dialysis (PD), and kidney transplantation (KT) patients in Korea.
We conducted a retrospective cohort study and data regarding Korean ESKD adults (aged ≥18 years) were obtained from the National Health Insurance Service of Korea from October 2020 to December 2021. We examined and compared the incidence of COVID-19-related infections and deaths among the patients receiving HD, PD, and KT.
Of all ESKD patients, 85,018 (68.1%) were on HD, 8,399 (6.7%) on PD, and 31,343 (25.1%) on KT. The COVID-19 incidence was 1.3% for HD, 1.2% for PD, and 1.5% for KT. COVID-19 mortality was 16.3% for HD, 12.2% for PD, and 4.7% for KT. PD patients had a lower incidence of infection compared to HD patients (odds ratio [OR], 0.76; 95% confidence interval [CI], 0.607-0.93), but KT patients had a significantly higher risk of infection (OR, 1.28; 95% CI, 1.13-1.44). Compared with HD, the risk of COVID-19-related death was not different for PD patients but was significantly lower for KT patients (hazard ratio, 0.55; 95% CI, 0.35-0.88).
COVID-19 incidence was lower in PD patients than in HD patients, but mortality was not different between them. KT was associated with a higher risk of COVID-19 infection but lower mortality compared to HD.
终末期肾病(ESKD)患者更容易受到病毒流行的影响,并且已知与普通人群相比,2019冠状病毒病(COVID-19)的发病率和死亡率更高。我们确定了韩国慢性血液透析(HD)、腹膜透析(PD)和肾移植(KT)患者中COVID-19的发病率和死亡率。
我们进行了一项回顾性队列研究,2020年10月至2021年12月期间,韩国终末期肾病成年患者(年龄≥18岁)的数据来自韩国国民健康保险服务中心。我们检查并比较了接受血液透析、腹膜透析和肾移植患者中COVID-19相关感染和死亡的发生率。
在所有终末期肾病患者中,85018例(68.1%)接受血液透析,8399例(6.7%)接受腹膜透析,31343例(25.1%)接受肾移植。血液透析患者的COVID-19发病率为1.3%,腹膜透析患者为1.2%,肾移植患者为1.5%。COVID-19死亡率血液透析患者为16.3%,腹膜透析患者为12.2%,肾移植患者为4.7%。与血液透析患者相比,腹膜透析患者的感染发生率较低(优势比[OR],0.76;95%置信区间[CI],0.607-0.93),但肾移植患者的感染风险显著更高(OR,1.28;95%CI,1.13-1.44)。与血液透析相比,腹膜透析患者COVID-19相关死亡风险无差异,但肾移植患者显著较低(风险比,0.55;95%CI,0.35-0.88)。
腹膜透析患者的COVID-19发病率低于血液透析患者,但两者死亡率无差异。与血液透析相比,肾移植与更高的COVID-19感染风险相关,但死亡率较低。